Detail
LncRNA Name | MEG3 |
Synonyms | MEG3, FP504, GTL2, LINC00023, NCRNA00023, PRO0518, PRO2160, onco-lncRNA-83, prebp1 |
Region | GRCh38_14:100779410-100861031 Sequence |
Ensembl | ENSG00000214548 |
RefSeq | NR_002766 |
Circulating | ✘ |
Drug-resisitant | ✘ |
Prognostic | ✘ |
MiRNA | ✔ |
Variant | ✘ |
TF | ✘ |
Methylation | ✔ |
Cancer Name | liver cancer |
ICD-0-3 | C22.0 |
Methods | RT-PCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP |
Sample | liver cancer tissue, liver cancer cell line (Hep3B) |
Expression Pattern | down-regulated |
Function Description | Mechanistically, MEG3 promotes the expression and maturition of miR122 which targets PKM2.Therefore,MEG3 decreases the expression and nuclear location of PKM2 dependent on miR122.Furthermore,MEG3 also inhibits CyclinD1 and C-Myc via PKM2 in liver cancer cells.On the other hand,MEG3 promotes B-catenin degradation through ubiquitin-proteasome system dependent on PTEN. Strikingly, MEG3 inhibits B-catenin activity through PKM2 reduction and PTEN increase.Significantly,we also found that excessive B-catenin abrogated the effect of MEG3 in liver cancer.MEG3 overexpression increased the PTEN 3-UTR mRNA methylation compared to control. MEG3 may be an underlying therapeutic target for LUAD functioning as ceRNAs for the regulation of miRNA-mRNA in lung adenocarcinoma. |
Pubmed ID | 29449541 |
Year | 2018 |
Title | Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting B-catenin by activating PKM2 and inactivating PTEN. |
External Links |
Links for MEG3 | GenBank HGNC lncrnadb Noncode |
Links for liver cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.